Edesa Biotech (EDSA) S-1/A 8 May 18 IPO registration (amended) Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Mar. 31, 2018
Document Information [Line Items]
Document Type	S1
Amendment Flag	false
Document Period End Date	Mar. 31, 2018
Entity Registrant Name	Stellar Biotechnologies, Inc.
Entity Central Index Key	1,540,159
Entity Filer Category	Non-accelerated Filer

Condensed Interim Consolidated

Condensed Interim Consolidated Balance Sheets - USD ($)	Mar. 31, 2018	Sep. 30, 2017	Sep. 30, 2016
Current assets:
Cash and cash equivalents	$ 3,293,010	$ 4,570,951	$ 7,416,904
Accounts receivable	62,798	1,287	85,813
Short-term investments	499,623	1,994,401	3,988,794
Inventory	205,364	68,114	249,430
Prepaid and other assets	209,980	123,694	358,714
Total current assets	4,270,775	6,758,447	12,099,655
Noncurrent assets:
Equity investment in joint venture	66,695	66,695	66,695
Property, plant and equipment, net	976,936	879,523	756,114
Deposits	15,340	15,340	15,340
Total noncurrent assets	1,058,971	961,558	838,149
Total Assets	5,329,746	7,720,005	12,937,804
Current liabilities:
Accounts payable and accrued liabilities	589,793	320,947	623,644
Total Current Liabilities	589,793	320,947	623,644
Commitments (Note 7)
Shareholders' equity:
Common shares, unlimited common shares authorized, no par value, 1,502,870 issued and outstanding at March 31, 2018 and September 30, 2017, 1,448,036 issued and outstanding at September 30, 2016.	48,351,701	48,351,701	47,280,792
Accumulated share-based compensation	4,533,568	4,439,400	5,394,763
Accumulated deficit	(48,145,316)	(45,392,043)	(40,361,395)
Total Shareholders' Equity	4,739,953	7,399,058	12,314,160
Total Liabilities and Shareholders' Equity	$ 5,329,746	$ 7,720,005	$ 12,937,804

Condensed Interim Consolidated3

Condensed Interim Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2018	Sep. 30, 2017	Sep. 30, 2016
Common shares, par value	$ 0	$ 0	$ 0
Common shares, shares issued	1,502,870	1,502,870	1,448,036
Common shares, shares outstanding	1,502,870	1,502,870	1,448,036

Condensed Interim Consolidated4

Condensed Interim Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2015
Revenues:
Product sales	$ 64,052	$ 13,019	$ 84,539	$ 154,875	$ 178,287	$ 1,239,689	$ 563,689
Contract services revenue	0	50,000	0	50,000	50,000	32,000	195,000
Revenues	64,052	63,019	84,539	204,875	228,287	1,271,689	758,689
Expenses:
Cost of sales and contract services	65,623	71,443	68,424	150,008	250,042	818,566	580,824
Costs of aquaculture	74,424	63,402	172,474	148,237	284,411	309,262	259,423
Research and development	493,873	329,371	1,124,907	790,236	1,973,400	1,729,445	1,029,489
General and administrative	773,989	746,360	1,452,470	1,678,427	2,944,980	3,322,772	3,227,545
Total Expenses	1,407,909	1,210,576	2,818,275	2,766,908	5,452,833	6,180,045	5,097,281
Loss from Operations	(1,343,857)	(1,147,557)	(2,733,736)	(2,562,033)	(5,224,546)	(4,908,356)	(4,338,592)
Other Income (Loss)
Foreign exchange loss	(16,218)	35,227	(34,147)	(42,163)	162,028	76,800	(653,333)
Gain (loss) in fair value of warrant liability					0	(211,956)	2,131,062
Investment income	7,548	8,653	15,410	15,647	32,670	24,632	54,634
Other Income (Loss), Total	(8,670)	43,880	(18,737)	(26,516)	194,698	(110,524)	1,532,363
Loss Before Income Tax	(1,352,527)	(1,103,677)	(2,752,473)	(2,588,549)	(5,029,848)	(5,018,880)	(2,806,229)
Income tax expense	0	0	800	800	800	7,200	36,800
Net Loss	$ (1,352,527)	$ (1,103,677)	$ (2,753,273)	$ (2,589,349)	$ (5,030,648)	$ (5,026,080)	$ (2,843,029)
Loss per common share:
Basic and diluted	$ (0.90)	$ (0.76)	$ (1.83)	$ (1.79)	$ (3.44)	$ (3.99)	$ (2.50)
Weighted average number of common shares outstanding:
Basic and diluted	1,502,870	1,448,036	1,502,870	1,448,036	1,462,459	1,260,902	1,136,709

Condensed Interim Consolidated5

Condensed Interim Consolidated Statements of Cash Flows - USD ($)	6 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2015
Cash Flows Used In Operating Activities:
Net loss	$ (2,753,273)	$ (2,589,349)	$ (5,030,648)	$ (5,026,080)	$ (2,843,029)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	95,894	90,720	179,322	149,565	159,521
Share-based compensation	94,168	64,794	115,546	259,379	267,222
Foreign exchange loss	34,147	42,163	(162,028)	(76,800)	653,333
(Gain) loss in fair value of warrant liability			0	211,956	(2,131,062)
Transfer of equipment to research and development expense	12,419	0
Changes in working capital items:
Accounts receivable	(61,549)	19,899	84,573	71,827	(113,917)
Inventory	(137,250)	(61,144)	181,316	307,850	(522,389)
Prepaid and other assets	(86,269)	(18,053)	235,001	(197,150)	(45,758)
Deposits			0	560	0
Accounts payable and accrued liabilities	268,845	(190,227)	(302,731)	(33,403)	77,018
Deferred revenue				(173,333)	86,666
Net cash used in operating activities	(2,532,868)	(2,641,197)	(4,699,649)	(4,505,629)	(4,412,395)
Cash Flows From Investing Activities:
Acquisition of property, plant and equipment	(205,891)	(126,876)	(302,733)	(402,271)	(274,589)
Purchase of short-term investments	(505,222)	(2,005,570)	(5,005,607)	(11,995,450)	(13,677)
Proceeds on sales and maturities of short-term investments	2,000,000	2,000,000	7,000,000	13,021,827	410,736
Contribution to joint venture			0	(66,695)	0
Net cash provided by (used in) investing activities	1,288,887	(132,446)	1,691,660	557,411	122,470
Cash Flows From Financing Activities:
Proceeds from issuance of common shares, net			0	6,277,500	0
Payments for share issuance costs			0	(332,764)	0
Proceeds from exercise of warrants and options			0	1,368,260	106,777
Net cash provided by financing activities			0	7,312,996	106,777
Effect of exchange rate changes on cash and cash equivalents	(33,960)	(42,039)	162,036	96,623	(629,808)
Net change in cash and cash equivalents	(1,277,941)	(2,815,682)	(2,845,953)	3,461,401	(4,812,956)
Cash and cash equivalents - beginning of period	4,570,951	7,416,904	7,416,904	3,955,503	8,768,459
Cash and cash equivalents - end of period	3,293,010	4,601,222	4,570,951	7,416,904	3,955,503
Cash (demand deposits)	2,788,805	850,224	3,847,655	972,412	3,955,503
Cash equivalents	504,205	3,750,998	723,296	6,444,492	0
Cash and cash equivalents	4,570,951	7,416,904	4,570,951	7,416,904	3,955,503
Supplemental cash flow information:
Cash paid during the period for taxes	$ 800	$ 800	800	7,200	36,800
Supplemental disclosure of non-cash transactions:
Share issuance costs withheld from escrow proceeds			$ 0	$ 472,500	$ 0

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($)	Total	Common Shares [Member]	Accumulated Share-Based Compensation [Member]	Accumulated Deficit [Member]
Balance at Sep. 30, 2014	$ 10,464,735	$ 37,883,877	$ 5,073,144	$ (32,492,286)
Balance (in shares) at Sep. 30, 2014		1,134,569
Proceeds from exercise of warrants	12,609	$ 12,609	0	0
Proceeds from exercise of warrants (in shares)		574
Transfer to common shares on exercise of warrants	9,574	$ 10,000	(426)	0
Proceeds from exercise of options	94,168	$ 94,168	0	0
Proceeds from exercise of options (in shares)		5,536
Transfer to common shares on exercise of options	0	$ 113,561	(113,561)	0
Share-based compensation	267,222	0	267,222	0
Net loss	(2,843,029)	0	0	(2,843,029)
Balance at Sep. 30, 2015	8,005,279	$ 38,114,215	5,226,379	(35,335,315)
Balance (in shares) at Sep. 30, 2015		1,140,679
Issuance of common shares	6,750,000	$ 6,750,000	0	0
Issuance of common shares (in shares)		241,071
Share issuance costs	(805,264)	$ (805,264)	0	0
Proceeds from exercise of warrants	1,368,260	$ 1,368,260	0	0
Proceeds from exercise of warrants (in shares)		66,286
Transfer to common shares on exercise of warrants	1,762,586	$ 1,853,581	(90,995)	0
Share-based compensation	259,379	0	259,379	0
Net loss	(5,026,080)	0	0	(5,026,080)
Balance at Sep. 30, 2016	12,314,160	$ 47,280,792	5,394,763	(40,361,395)
Balance (in shares) at Sep. 30, 2016		1,448,036
Issuance of performance shares	0	$ 1,070,909	(1,070,909)	0
Issuance of performance shares (in shares)		54,834
Share-based compensation	115,546	$ 0	115,546	0
Net loss	(5,030,648)	0	0	(5,030,648)
Balance at Sep. 30, 2017	7,399,058	$ 48,351,701	$ 4,439,400	$ (45,392,043)
Balance (in shares) at Sep. 30, 2017		1,502,870
Net loss	(2,753,273)
Balance at Mar. 31, 2018	$ 4,739,953

Nature of Operations

Nature of Operations	6 Months Ended	12 Months Ended
	Mar. 31, 2018	Sep. 30, 2017
Nature of Operations [Abstract]
Nature of Operations [Text Block]	1. Nature of Operations Stellar Biotechnologies, Inc. (the Company) is organized under the laws of British Columbia, Canada. The Company’s business is the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). The Company markets and distributes its KLH products to biotechnology and pharmaceutical companies, academic institutions, and clinical research organizations primarily in Europe, Asia, and the United States. The Company’s common shares have been listed for trading on The Nasdaq Capital Market in the United States under the symbol “SBOT” since November 5, 2015. In April 2010, the Company changed its name from CAG Capital, Inc. to Stellar Biotechnologies, Inc. and completed a reverse merger transaction with Stellar Biotechnologies, Inc., a California corporation, which was founded in September 1999, and remains the Company’s wholly-owned subsidiary and principal operating entity. In January 2017, the California subsidiary and the Company established a wholly-owned Mexican subsidiary under the name BioEstelar, S.A. de C.V. in Ensenada, Baja California to perform aquaculture research and development activities in Mexico. The Company’s executive offices are located at 332 E. Scott Street, Port Hueneme, California, 93041, USA, and its registered and records office is 1500 Royal Centre, 1055 West Georgia Street, Vancouver, BC, V6E 4N7, Canada. Management Plans and Going Concern Company operations have historically been funded by the issuance of common shares, exercise of warrants, grant revenues, contract services revenue and product sales. For the six months ended March 31, 2018 and 2017, the Company reported net losses of approximately $2.8 million and $2.6 million, respectively. As of March 31, 2018, the Company had an accumulated deficit of approximately $48.1 million and working capital of approximately $3.7 million. While the Company plans to finance company operations in the near term with cash on hand and product sales, management expects to continue incurring losses for the foreseeable future. Management is taking action to adjust planned expenditures based on a number of factors including the size and timing of capital expenditures, staffing levels, inventory levels, and the status of customer clinical trials. Management also seeks to expand the customer base for existing marketed products, and intends to secure additional financing through debt and/or equity financings, including transactions with strategic customers and partners that may include debt and/or equity arrangements. However, without raising additional capital to pursue our business plan, there is substantial doubt about the Company’s ability to continue as a going concern beyond one year from the date of the issuance of the Company’s financial statements in this Form 10-Q.	1. Nature of Operations Stellar Biotechnologies, Inc. (the Company) is organized under the laws of British Columbia, Canada. The Company’s business is the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). The Company markets and distributes its KLH products to biotechnology and pharmaceutical companies, academic institutions, and clinical research organizations primarily in Europe, North American and Asia. The Company’s common shares have been listed for trading on The Nasdaq Capital Market in the United States under the symbol SBOT since November 5, 2015. From January 15, 2013 through November 4, 2015, the Company’s common shares were quoted in the United States on the U.S. OTCQB Marketplace Exchange under the symbol SBOTF. From April 19, 2010 to April 8, 2016 the Company’s common shares were listed in Canada on the TSX Venture Exchange as a Tier 2 issue under the trading symbol KLH. In April 2010, the Company changed its name from CAG Capital, Inc. to Stellar Biotechnologies, Inc. and completed a reverse merger transaction with Stellar Biotechnologies, Inc., a California corporation, which was founded in September 1999, and remains the Company’s wholly-owned subsidiary and principal operating entity. In January 2017, the California subsidiary and the Company established a wholly-owned Mexican subsidiary under the name BioEstelar, S.A. de C.V. in Ensenada, Baja California to perform aquaculture research and development activities in Mexico. The Company’s executive offices are located at 332 E. Scott Street, Port Hueneme, California, 93041, USA, and its registered and records office is Royal Centre, 1055 West Georgia Street, Suite 1500, Vancouver, BC, V6E 4N7, Canada. Functional Currency The consolidated financial statements of the Company are presented in U.S. dollars, which is the Company’s functional currency, unless otherwise stated. Management Plans Company operations have historically been funded by the issuance of common shares, exercise of warrants, grant revenues, contract services revenue and product sales. For the fiscal years 2017, 2016, and 2015, the Company reported net losses of approximately $ 5.0 5.0 2.8 45.4 6.4

Basis of Presentation

Basis of Presentation	6 Months Ended	12 Months Ended
	Mar. 31, 2018	Sep. 30, 2017
Basis of Presentation [Abstract]
Basis of Accounting [Text Block]	2. Basis of Presentation The accompanying unaudited condensed interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q. They do not include all information and footnotes necessary for a fair presentation of financial position, results of operations and cash flows in conformity with U.S. GAAP for complete financial statements. These condensed interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2017. The accompanying condensed interim consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries, Stellar Biotechnologies, Inc., a California corporation in the U.S. and BioEstelar, S.A. de C.V. a Baja California corporation in Mexico. All significant intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normal recurring adjustments and accruals) considered necessary for a fair presentation of the results of operations for the period presented have been included in the interim period. Operating results for the six months ended March 31, 2018 are not necessarily indicative of the results that may be expected for other interim periods or the fiscal year ending September 30, 2018. The condensed interim consolidated financial data at September 30, 2017 is derived from audited financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2017, as filed on December 1, 2017 with the SEC. The preparation of financial statements in conformity with U.S. GAAP for interim financial information requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from these estimates. Functional Currency The condensed interim consolidated financial statements of the Company are presented in U.S. dollars, unless otherwise stated, which is the Company’s functional currency.	2. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and include the accounts of the Company, its wholly-owned subsidiaries, Stellar Biotechnologies, Inc., a California corporation in the U.S. and BioEstelar, S.A. de C.V. a Baja California corporation in Mexico. All significant intercompany balances and transactions have been eliminated in consolidation.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	3. Significant Accounting Policies a) Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reported periods. These estimates include warrant liabilities, share-based compensation, intangible assets, valuation of accounts receivable, valuation of inventory, and income taxes. Actual outcomes could differ from these estimates. These consolidated financial statements include estimates, which by their nature are uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements, and may require accounting adjustments based on future periods if the revision affects both current and future periods. These estimates are based on historical experience, current and future economic conditions and other factors, including expectations of future events that are believed to be reasonable under the circumstances. b) Cash and Cash Equivalents Cash and cash equivalents consist of demand deposits with financial institutions and highly liquid investments which are readily convertible into cash with maturities of three months or less when purchased. c) Investments Investments at September 30, 2017 and 2016 consisted of U.S. Treasury bills with original maturities between 13 and 52 weeks. They are classified as held-to-maturity and are reported at amortized cost, which approximates fair value. The Company regularly reviews these investments to determine whether any decline in fair value below the amortized cost basis has occurred that is other than temporary. If a decline in fair value has occurred that is determined to be other than temporary, the cost basis of the investment is written down to fair value. d) Allowance for Doubtful Accounts Receivable The Company assesses the collectability of its accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions and credit status of its customers. As of September 30, 2017 and 2016, all outstanding accounts receivable were deemed to be fully collectible, and therefore, no allowance for doubtful accounts was recorded. e) Inventory The Company records inventory at the lower of cost or market, with market not in excess of net realizable value. Raw materials are measured using FIFO (first-in first-out) cost. Work in process and finished goods are measured using average cost. f) Property, Plant and Equipment Property, plant and equipment are recorded at cost less accumulated depreciation and accumulated impairment losses, if any. Depreciation is recorded on the straight-line method over useful lives ranging from 1.5 15 g) Impairment of Long-Lived Assets If indicators of impairment exist, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, the amount of such impairment is measured by comparing the carrying value of the asset to the fair value of the asset and the Company records the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. h) Fair Value of Financial Instruments The Company uses the fair value measurement framework for valuing financial assets and liabilities measured on a recurring basis in situations where other accounting pronouncements either permit or require fair value measurements. See Note 10 for fair value measurements. Revenue Recognition Product Sales The Company recognizes product sales when KLH product is shipped (for which the risk is typically transferred upon delivery to the shipping carrier) and there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collectability is reasonably assured. The Company documents arrangements with customers with purchase orders and sales agreements. Product sales include sales made under supply agreements with customers for a fixed price per gram of KLH products based on quantities ordered. Supply agreements are typically on a non-exclusive basis except within that customer’s field of use. Contract services revenue The Company recognizes contract services revenue when contract services have been performed and reasonable assurance exists regarding measurement and collectability. An appropriate amount will be recognized as revenue in the period that the Company is assured of fulfilling the contract requirements. Amounts received in advance of performance of contract services are recorded as deferred revenue. Contract services include services performed under collaboration agreements and technology transfer and purchase agreement. Research and Development Research and development expenses principally consist of personnel costs related to the Company’s research and development staff as well as depreciation of research and development assets. Research and development expenses also include costs incurred for laboratory supplies , KLH designated for internal research use only Research and development costs are expensed as incurred. Share-Based Compensation The Company grants options to buy common shares of the Company to its directors, officers, employees and consultants, and grants other equity-based instruments to non-employees. The fair value of share-based compensation is measured on the date of grant, using the Black-Scholes option valuation model and is recognized over the vesting period net of estimated forfeitures for employees or the service period for non-employees. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. l) Foreign Exchange Items included in the financial statements of the Company’s subsidiaries are measured using the currency of the primary economic environment in which the entity operates (the functional currency). The functional currency of the parent and its subsidiaries is the U.S. dollar. Transactions in currencies other than the U.S. dollar are recorded at exchange rates prevailing on the dates of the transactions. m) Income Taxes Income tax expense comprises current and deferred tax. Income tax is recognized in income or loss except to the extent that it relates to items recognized directly in equity. Current tax expense is the expected tax payable on taxable income for the year, using tax rates enacted or substantively enacted at year-end, adjusted for amendments to tax payable with regards to previous years. Deferred tax is recorded using the liability method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Temporary differences are not provided for relating to goodwill not deductible for tax purposes. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the balance sheet date. A deferred tax asset is recognized only to the extent that it is more likely than not that future taxable profits will be available against which the asset can be utilized. To the extent that the Company does not consider it more likely than not that a deferred tax asset will be recovered, it provides a valuation allowance against that excess. The Company periodically evaluates its tax positions to determine whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities. The Company has not incurred any interest or penalties as of September 30, 2017 with respect to uncertain income tax matters. The Company does not expect that there will be unrecognized tax benefits of a significant nature that will increase or decrease within 12 months of the reporting date. The Company files income tax returns in the U.S. federal and state jurisdictions and in Canada. Mexico tax returns are on a calendar year basis. Management believes that there are no material uncertain tax positions that would impact the accompanying consolidated financial statements. The Company's policy is to recognize interest and penalties related to unrecognized tax benefits in income tax expense. The Company may be subject to examination by the Internal Revenue Service for tax years 2013 through 2016 and by the Canada Revenue Agency for tax years 2013 through 2017. The Company may also be subject to examination on certain state, local and other foreign jurisdictions for the tax years 2012 through 2017. n) Earnings (Loss) Per Share Basic earnings (loss) per share is calculated by dividing income available to common shareholders by the weighted average number of common shares outstanding during the period. The computation of diluted earnings (loss) per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on earnings (loss) per share. The dilutive effect of convertible securities is reflected in diluted earnings per share by application of the “if converted” method. The dilutive effect of outstanding options and warrants and their equivalents is reflected in diluted earnings per share by application of the treasury stock method. Conversion of outstanding warrants, broker units and options would have an antidilutive effect on loss per share for the years ended September 30, 2017, 2016 and 2015 and are therefore excluded from the computation of diluted loss per share. o) Segments The Company operates in one reportable segment and, accordingly, no segment disclosures have been presented. All equipment, leasehold improvements and other fixed assets owned by the Company are physically located within the United States (except for insignificant leasehold improvements under evaluation in Baja California, Mexico), and all supply, collaboration and licensing agreements are denominated in U.S. dollars. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued guidance codified in Accounting Standards Codification (ASC) 606 Revenue Recognition – Revenue from Contracts with Customers which amends the guidance in ASC 605, Revenue Recognition and adds a new Subtopic to the Codification, ASC 340-40, Other Assets and Deferred Costs: Contracts with Customers. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer; Step 2: Identify the performance obligations in the contract; Step 3: Determine the transaction price; Step 4: Allocate the transaction price to the performance obligations in the contract; and Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). In August 2015, the FASB issued an accounting update to defer the effective date by one year for public entities such that it is now effective for public entities for annual reporting periods beginning after December 15, 2017, including interim periods within those years, with early application permitted by one year. Subsequently, the FASB issued supplemental adoption guidance and clarification to ASC 606 related to principal vs. agent considerations, identifying performance obligations and licensing, technical corrections and improvements, which must be adopted at the same time as ASC 606. These standards are effective for the Company during the fiscal year ending September 30, 2019. Management is in the process of assessing the impact this guidance will have on the Company’s consolidated financial statements. We anticipate adoption of ASC 606 using the modified retrospective method with a cumulative catch-up adjustment to the opening balance sheet of retained earnings at the effective date, during the first quarter of fiscal 2019. The Company will continue to review separate performance obligations, potential disclosures, and the method of adoption in order to complete the evaluation of the impact on the consolidated financial statements. In July 2015, FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory within those years In January 2016, the FASB issued ASU 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities primarily affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, ASU 2016-01 The guidance is effective for public entities for fiscal years beginning after December 15, 2017, including interim periods within those years, with early adoption permitted. These standards are effective for the Company during the fiscal year ending September 30, 2019. . In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) Management is in the process of assessing the impact of ASU 2016-02 on the Company’s consolidated financial statements. We anticipate adoption of ASU 2016-02, will result in lease liabilities and right-of-use assets financial statements for several long-term operating leases. In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows . The amended guidance is effective for public entities for fiscal years beginning after December 15, 2016, including interim periods within those years, with early adoption permitted. ASU 2016-09 on financial statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Management is in the process of assessing the impact of ASU 2016-13 on the Company’s consolidated financial statements . In May 2017, the FASB issued ASU 2017-09, Scope of Modification Accounting Compensation-Stock Compensation

Investments

Investments	6 Months Ended	12 Months Ended
	Mar. 31, 2018	Sep. 30, 2017
Investments [Abstract]
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	3. Investments Short-term investments consisted of U.S. Treasury Bills at March 31, 2018 and September 30, 2017. U.S. Treasury Bills are carried at amortized cost which approximates fair value and are classified as held-to-maturity investments.	4. Investments Short-term investments consisted of the following: September 30, September 30, 2017 2016 U.S. Treasury Bills $ 1,994,401 $ 3,988,794 U.S. Treasury Bills are carried at amortized cost which approximates fair value and classified as held-to-maturity investments.

Inventory

Inventory	6 Months Ended	12 Months Ended
	Mar. 31, 2018	Sep. 30, 2017
Inventory [Abstract]
Inventory Disclosure [Text Block]	4. Inventory Raw materials include inventory of manufacturing supplies. Work in process includes manufacturing supplies, direct and indirect labor, contracted manufacturing and testing, and allocated manufacturing overhead for inventory in process at the end of the period. Finished goods include products that are complete and available for sale. At March 31, 2018 and September 30, 2017, the Company recorded work in process and finished goods inventory only for those products with recent sales levels to evaluate net realizable value. March 31, September 30, 2018 2017 Raw materials $ 35,514 $ 21,761 Work in process 69,100 - Finished goods 100,750 46,353 $ 205,364 $ 68,114	5. Inventory Raw materials include inventory of manufacturing supplies. Work in process includes manufacturing supplies, direct and indirect labor, contracted manufacturing and testing, and allocated manufacturing overhead for inventory in process at the end of the year. Finished goods include products that are complete and available for sale. At September 30, 2017 and 2016, the Company recorded work in process and finished goods inventory only for those products with recent sales levels to evaluate net realizable value. Inventory consisted of the following: September 30, September 30, 2017 2016 Raw materials $ 21,761 $ 38,764 Work in process - 43,498 Finished goods 46,353 167,168 $ 68,114 $ 249,430

Property, Plant and Equipment,

Property, Plant and Equipment, net	6 Months Ended	12 Months Ended
	Mar. 31, 2018	Sep. 30, 2017
Property, Plant and Equipment, net [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	5. Property, Plant and Equipment, net March 31, September 30, 2018 2017 Aquaculture system $ 126,257 $ 126,257 Laboratory facilities 62,033 62,033 Computer and office equipment 119,199 117,840 Manufacturing and laboratory equipment 1,039,643 982,439 Vehicles 77,994 77,994 Leasehold improvements 342,935 337,060 1,768,061 1,703,623 Less: accumulated depreciation (1,054,907) (969,418) Depreciable assets, net 713,154 734,205 Construction in progress 263,782 145,318 $ 976,936 $ 879,523 Depreciation and amortization expense amounted to approximately $ 96,000 91.000	6. Property, Plant and Equipment, net September 30, September 30, 2017 2016 Aquaculture system $ 126,257 $ 126,257 Laboratory facilities 62,033 62,033 Computer and office equipment 117,840 102,030 Tools and equipment 982,439 894,319 Vehicles 77,994 49,347 Leasehold improvements 337,060 282,305 1,703,623 1,516,291 Less: accumulated depreciation (969,418) (793,057) Depreciable assets, net 734,205 723,234 Construction in progress 145,318 32,880 $ 879,523 $ 756,114 Depreciation expense amounted to $ 179,322 149,565 159,521

Commitments

Commitments	6 Months Ended	12 Months Ended
	Mar. 31, 2018	Sep. 30, 2017
Commitments [Abstract]
Commitments and Contingencies Disclosure [Text Block]	6. Commitments Operating leases The Company leases buildings and facilities used in its operations under two sublease agreements. In June 2015, the Company exercised its option to extend these sublease agreements for an additional five-year term beginning in October and November 2015. The Company negotiated an option to extend the leases for two additional five-year terms. The Company leases facilities used for executive offices and laboratories and pays a portion of the common area maintenance. In July 2016, the Company extended this lease for a two-year term, with options to renew for three successive two-year terms. The Company leases undeveloped land in Baja California, Mexico to assess the potential development of an additional aquaculture locale and expansion of production. The lease term was three years from June 2015 with options to extend the lease for 30 years. In February 2018, the lease term was extended for two years without further rent payments. The Company may terminate early with 30 days’ notice. The rent has been prepaid through June 2018, and is not included in the future minimum lease payments below. The Company has a related agreement with the lessor to collaborate on the design, expansion and development of marine aquaculture resources and KLH production facilities on the leased property. Under that agreement, the Company was responsible for certain leasehold improvements including construction of structures and a power-generating facility, which are owned by the Company. The Company reimburses the lessor for local operational support. The collaboration agreement expires in June 2018, unless terminated earlier. Six Months Ending September 30, 2018 71,000 Year Ending September 30, 2019 106,000 Year Ending September 30, 2020 106,000 Year Ending September 30, 2021 6,000 $ 289,000 Rent expense on these lease agreements amounted to approximately $ 120,000 119,000 Purchase obligations The Company has commitments totaling approximately $ 153,000 Supply agreements The Company has commitments under supply agreements with customers for fixed prices per gram of KLH in connection with clinical trials on a non-exclusive basis except within that customer’s field of use. The expiration dates of these supply agreements range from October 2019 to February 2022, and are generally renewable upon written request of the customer. Joint venture agreement In May 2016, the Company entered into a joint venture agreement with another party for the formation of a joint venture company to manufacture and sell conjugated therapeutic vaccines. The joint venture is organized as a French simplified corporation. The Company holds a 30% equity interest in the joint venture in exchange for an initial capital contribution of €120,000. One-half of the initial contribution, approximately $67,000, was paid during the year ended September 30, 2016 with the balance due upon the occurrence of certain defined future events. The Company will also provide the joint venture additional financing as may be required, on a pro rata basis in line with our equity interest. According to the joint venture agreement, if certain milestones were not achieved by December 31, 2017, the joint venture would be dissolved, unless (i) the parties mutually agree to pursue the joint venture arrangement, or (ii) either party decides to purchase the equity interests of the other party. In February 2018, the parties renewed and amended the joint venture agreement to extend this deadline to December 31, 2018. Each of the parties is entitled, upon the occurrence of certain defined events, to acquire the interest of the other party. Except as described herein, the joint venture has an initial ten-year term, renewable for successive five-year terms. If either party provides notice at least six months prior to the expiration date of an applicable term that it does not wish to continue its participation in the joint venture, the other party will have a right to acquire all of such terminating party’s equity interests in the joint venture. In connection with the formation of the joint venture and the execution of its strategy, the parties intend over time to enter into an exclusive supply agreement within a limited field of use for Stellar to supply KLH to the joint venture, a supply agreement designating the joint venture as the exclusive manufacturer and supplier of the other party’s vaccines, and services agreements for the provision of various knowledge and expertise by each of the parties. Licensing agreement and technology transfer agreement In July 2013, the Company acquired the exclusive, worldwide license to certain patented technology for the development of human immunotherapies against Clostridium difficile As a result of the termination of the License Agreement, there are no early termination penalties and no further annual licensing fees, contingent milestone payments, royalties, sub-licensing fees or other financial obligations payable by the Company to the Licensor. Retirement savings plan 401(k) contributions The Company sponsors a 401(k) retirement savings plan that requires an annual non-elective safe harbor employer contribution of 3 100 38,000 32,000 Related party commitments On August 14, 2002, through its California subsidiary, the Company entered into a patent royalty agreement with a director and officer of the Company, whereby he would receive royalty payments in exchange for assignment of his patent rights to the Company. The royalty is 5% of gross receipts from products using this invention in excess of $500,000 annually. The Company’s current operations utilize this invention. There was no royalty expense incurred during the six months ended March 31, 2018 and 2017.	7. Commitments Operating leases The Company leases buildings and facilities used in its operations under two sublease agreements. In June 2015, the Company exercised its option to extend these sublease agreements for an additional five-year term beginning in October and November 2015. The Company negotiated an option to extend the leases for two additional five-year terms. The Company leases facilities used for executive offices and laboratories. The Company must pay a portion of the common area maintenance. In July 2016, the Company extended this lease for a two-year term, with options to renew for three successive two-year terms. The Company leases undeveloped land in Baja California, Mexico to assess the potential development of an additional aquaculture locale and expansion of production. The lease term is three years from June 2015 with options to extend the lease for 30 years. The Company may terminate early with 30 days’ notice. The rent has been prepaid, and is not included in the future minimum lease payments below. The Company has a related agreement with the lessor to collaborate on the design, expansion and development of marine aquaculture resources and KLH production facilities on the leased property. Under that agreement, the Company is responsible for certain leasehold improvements including construction of structures and a power-generating facility, which will be owned by the Company. The Company will reimburse the lessor for local operational support. The collaboration agreement expires in June 2018, unless terminated earlier. Aggregate future minimum lease payments at September 30, 2017 are as follows: For The Year Ending September 30, 2018 160,000 2019 106,000 2020 106,000 2021 6,000 $ 378,000 Rent expense on these lease agreements amounted to approximately $238,000, $235,000 and $192,000 for the years ended September 30, 2017, 2016 and 2015, respectively. Purchase obligations The Company has commitments totaling approximately $252,000 at September 30, 2017, for signed agreements with contract research organizations, consultants and construction contractors. All purchase obligations are expected to be fulfilled within the next 12 months, except for approximately $65,100, which is expected to be fulfilled in the following fiscal year. Supply agreements The Company has commitments under supply agreements with customers for fixed prices per gram of KLH in connection with clinical trials on a non-exclusive basis except within that customer’s field of use. The expiration dates of these supply agreements range from October 2019 to February 2022, and are generally renewable upon written request of the customer. Joint venture agreement In May 2016, the Company entered into a joint venture agreement with another party for the formation of a joint venture company to manufacture and sell conjugated therapeutic vaccines. The joint venture is organized as a French simplified corporation. The Company holds a 30% equity interest in the joint venture in exchange for an initial capital contribution of €120,000. One-half of the initial contribution, approximately $67,000, was paid during the year ended September 30, 2016 with the balance due upon the occurrence of certain defined future events. The Company will also provide the joint venture additional financing as may be required, on a pro rata basis in line with our equity interest. If the joint venture does not achieve certain milestones by December 31, 2017, the joint venture will be dissolved, unless (i) the parties mutually agree to pursue the joint venture arrangement, or (ii) either party decides to purchase the equity interests of the other party. These milestones have not been achieved, and the parties have discussed their mutual desire to extend the deadline. Each of the parties is entitled, upon the occurrence of certain defined events, to acquire the interest of the other party. Except as described herein, the joint venture has an initial ten-year term, renewable for successive five-year terms. If either party provides notice at least six months prior to the expiration date of an applicable term that it does not wish to continue its participation in the joint venture, the other party will have a right to acquire all of such terminating party’s equity interests in the joint venture. In connection with the formation of the joint venture and the execution of its strategy, the parties intend over time to enter into an exclusive supply agreement within a limited field of use for Stellar to supply KLH to the joint venture, a supply agreement designating the joint venture as the exclusive manufacturer and supplier of the other party’s vaccines, and services agreements for the provision of various knowledge and expertise by each of the parties. Licensing agreement and technology transfer agreement In July 2013, the Company acquired the exclusive, worldwide license to certain patented technology for the development of human immunotherapies against Clostridium difficile In March 2017, (i) the Company entered into an agreement to terminate the License Agreement, (ii) the Company concurrently entered into a technology transfer and purchase agreement (the Transfer Agreement) with a vaccine biotechnology company (the Transferee), and (iii) the Licensor and Transferee entered into a direct licensing arrangement relating to the patented C. diff technology. Under the Transfer Agreement, the Company transferred to the Transferee its proprietary rights and know-how of immunogens and vaccine technology for C. diff, in exchange for an upfront payment and a percentage of future fees, milestone payments, sublicensing income and royalties, if any, paid by the Transferee or its assigns to the Licensor. As a result of the termination of the License Agreement, there are no early termination penalties and no further annual licensing fees, contingent milestone payments, royalties, sub-licensing fees or other financial obligations payable by the Company to the Licensor. Retirement savings plan 401(k) contributions The Company sponsors a 401(k) retirement savings plan that requires an annual non-elective safe harbor employer contribution of 3% of eligible employee wages. All employees over 21 years of age are eligible beginning the first payroll after 3 consecutive months of employment. Employees are 100% vested in employer contributions and in any voluntary employee contributions. Contributions to the 401(k) plan were approximately $62,000, $64,000 and $58,000 for the years ended September 30, 2017, 2016 and 2015, respectively. Related party commitments: Patent oyalty agreement On August 14, 2002, through its California subsidiary, the Company entered into an agreement with a director and officer of the Company, where he would receive royalty payments in exchange for assignment of his patent rights to the Company. The royalty is 5% of gross receipts from products using this invention in excess of $500,000 annually. The Company’s current operations utilize this invention. Royalty expense incurred during the years ended September 30, 2016 and 2015 was approximately $35,500 and $1,500. There was no royalty expense incurred during the year ended September 30, 2017. Collaboration agreement In December 2013, the Company entered into a collaboration agreement with a privately-held Taiwanese biopharmaceuticals manufacturer which expired in accordance with its terms in December 2015. Under the terms of the agreement, the Company was responsible for the production and delivery of GMP grade KLH for evaluation as a carrier molecule in the collaboration partner’s potential manufacture of OBI-822 (Adagloxad Simolenin) active immunotherapy. The Company was also responsible for method development, product formulation, and process qualification for certain KLH reference standards. The collaboration partner was responsible for development objectives and product specifications. The agreement provided for the collaboration partner to pay fees for certain expenses and costs associated with the collaboration. Subject to certain conditions and timing, the collaboration also provided for the parties to negotiate a commercial supply agreement for Stellar KLH which was executed in February 2017. A member of the Company’s Board of Directors currently serves as the manufacturer’s general manager and chair of its board of directors.

Share Capital

Share Capital	6 Months Ended	12 Months Ended
	Mar. 31, 2018	Sep. 30, 2017
Share Capital [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	7. Share Capital On May 4, 2018, the Company effected a share consolidation (reverse split) of the Company's common shares at a ratio of 1-for-7. As a result of the reverse split, every seven shares of the issued and outstanding common shares, without par value, consolidated into one newly-issued outstanding common share, without par value. Each fractional share remaining after the reverse split that was less than one-half of a share was cancelled and each fractional share that was at least one-half of a share was changed to one whole share. The reverse split reduced the number of common shares outstanding from 10,520,096 to 1,502,870 after fractional share rounding. The number of warrants and options were proportionately adjusted by the split ratio and the exercise prices correspondingly increased by the same split ratio. All shares and exercise prices are presented on a post-split basis in these condensed interim consolidated financial statements. Black-Scholes option valuation model The Company uses the Black-Scholes option valuation model to determine the fair value of warrants and share options. Option valuation models require the input of highly subjective assumptions including the expected price volatility. The Company has used historical volatility to estimate the volatility of the share price. Changes in the subjective input assumptions can materially affect the fair value estimates, and therefore the existing models do not necessarily provide a reliable single measure of the fair value of the Company’s warrants and share options. Warrants There were 180,805 warrants outstanding at March 31, 2018 with an exercise price of $31.50 and expiry date of January 6, 2022. There were no warrants granted or exercised during the period from September 30, 2016 to March 31, 2018. The weighted average contractual life remaining on the outstanding warrants at March 31, 2018 is 45 months. Share Options The Company has an incentive compensation plan adopted in 2017 (the Incentive Plan) administered by the Board of Directors, which amended and restated the 2013 fixed share option plan. Options, restricted shares and restricted share units are eligible for grants under the Incentive Plan. The number of shares available for issuance under the Incentive Plan is 228,143, including shares available for the exercise of outstanding options under the 2013 fixed share option plan. No restricted shares or restricted share units have been granted as of March 31, 2018. The exercise price of an option is set at the closing price of the Company’s common shares on the date of grant. Share options granted to directors, officers, employees and certain individual consultants for past service are subject to the following vesting schedule: (a) one-third shall vest immediately, (b) one-third shall vest at 12 months from the date of grant and (c) one-third shall vest at 18 months from the date of grant. Share options granted to directors, officers, employees and certain individual consultants for future service are subject to the following vesting schedule: (x) one-third shall vest at 12 months from the date of grant, (y) one-third shall vest at 24 months from the date of grant and (z) one-third shall vest at 36 months from the date of grant. Share options granted to certain individual investor relations consultants are subject to the following vesting schedule: (aa) 25% shall vest at 3 months from the date of grant, (bb) 25% shall vest at 6 months from the date of grant, (cc) 25% shall vest at 12 months from the date of grant and (dd) 25% shall vest at 15 months from the date of grant. Weighted Number of Average Options Exercise Price Balance - September 30, 2016 77,015 $ 37.03 Granted 10,229 13.23 Expired (4,033) 77.98 Expired (24,500) 20.30 CDN $ Balance - September 30, 2017 58,711 $ 40.18 Granted 29,426 5.88 Expired (1,671) 112.56 Expired (5,679) 36.19 CDN $ Balance - March 31, 2018 80,787 $ 26.46 The weighted average contractual life remaining on the outstanding options is 50 months. Number of Exercisable at Options March 31, 2018 Range of exercise prices Expiry Dates 13,479 13,479 CDN$15.00 - 35.00 Apr 2019-Dec 2019 40,641 15,859 $5.00 - 20.00 Sep 2023-Mar 2025 17,265 17,265 CDN$40.00 - 70.00 Aug 2018-Jun 2022 2,114 2,114 $50.00 - 60.00 Dec 2022 3,073 3,073 CDN$105.00 - 140.00 Nov 2018-Nov 2021 4,215 4,215 $120.00 - 130.00 Nov 2020 80,787 56,005 Six Months Ended March 31, March 31, 2018 2017 Risk free interest rate 2.13 % 1.44 % Expected life (years) 7.00 7.00 Expected share price volatility 155 % 166 % Expected dividend yield 0 % 0 % The weighted average fair value of share options granted during the six months ended March 31, 2018 and 2017 was $ 5.67 12.88 As of March 31, 2018, the Company had approximately $ 137,000 34 There were no options exercised during the six months ended March 31, 2018 and 2017. There was no intrinsic value of the vested options at March 31, 2018.	8. Share Capital Years Ended September 30, September 30, September 30, 2017 2016 2015 Number of common shares issued 54,834 307,357 6,110 Issuance of common shares $ - $ 6,750,000 $ - Share issuance costs - (805,264) - Proceeds from exercise of warrants - 1,368,260 12,609 Transfer to common shares on issuance of performance shares 1,070,909 - - Transfer to common shares on exercise of warrants - 1,853,581 10,000 Proceeds from exercise of options - - 94,168 Transfer to common shares on exercise of options - - 113,561 Share-based compensation 115,546 259,379 267,222 Reverse Share Split On September 2, 2015, the Company effected a share consolidation (reverse split) of the Company's common shares at a ratio of 1-for-10. As a result of the reverse split, every ten shares of the issued and outstanding common shares, without par value, consolidated into one newly-issued outstanding common share, without par value. Each fractional share remaining after the reverse split that was less than one-half of a share was cancelled and each fractional share that was at least one-half of a share was changed to one whole share. Performance Shares Pursuant to a performance share plan approved by shareholders in 2010, 142,857 At September 30, 2017, all vested performance shares under the plan have been issued, and the performance share plan was terminated. Black-Scholes option valuation model The Company uses the Black-Scholes option valuation model to determine the fair value of warrants, broker units and share options. Option valuation models require the input of highly subjective assumptions including the expected price volatility. The Company has used historical volatility to estimate the volatility of the share price. Changes in the subjective input assumptions can materially affect the fair value estimates, and therefore the existing models do not necessarily provide a reliable single measure of the fair value of the Company’s warrants, broker units and share options. Warrants Weighted Number of Average Warrants Exercise Price Balance - September 30, 2015 146,110 $ 63.28 Granted 180,805 31.50 Granted 5,715 28.00 CDN $ Exercised (60,572) 28.00 CDN $ Expired (85,538) 93.31 Expired (5,715) 28.00 CDN $ Balance - September 30, 2016 and 2017 180,805 $ 31.50 There are no outstanding warrants with exercise prices denominated in Canadian dollar at September 30, 2017. The weighted average contractual life remaining on the outstanding warrants at September 30, 2017 is 51 Number of Exercise Price Warrants Expiry Date $ 31.50 180,805 January 6, 2022 180,805 Warrant Liability All warrants with exercise prices denominated in Canadian dollars were exercised or expired. Therefore, there is no outstanding warrant liability at September 30, 2017. Equity offerings conducted by the Company in prior years included the issuance of warrants with exercise prices denominated in Canadian dollars. The Company’s functional currency is the U.S. dollar. As a result of having exercise prices denominated in other than the Company’s functional currency, those warrants met the definition of derivatives and were therefore classified as derivative liabilities measured at fair value with adjustments to fair value recognized through the consolidated statements of operations. The fair value of those warrants was determined using the Black-Scholes option valuation model at the end of each reporting period. On the date those warrants were exercised, the fair value of warrant liability was reclassified to common shares along with the proceeds from the exercise. If those warrants expired, the related decrease in warrant liability was recognized in profit or loss, as part of the change in fair value of warrant liability. There was no cash flow impact as a result of this accounting treatment. Years Ended September 30, September 30, 2016 2015 Risk free interest rate 0.48 % 0.44 % Expected life (years) 0.04 0.40 Expected share price volatility 92 % 92 % There were no warrants exercised during the year ended September 30, 2017. Year Ended September 30, 2016 Risk free interest rate 0.52 % Expected life (years) 0.01 Expected share price volatility 91 % Expected dividend yield 0 % There were no warrants granted during the years ended September 30, 2017 or 2015. Broker units The Company granted broker units as finders’ fees in conjunction with equity offerings in prior years. Broker units were fully vested when granted and allowed the holders to purchase equity units. A unit consisted of one common share and either one whole warrant or one half warrant. Weighted Number of Average Units Exercise Price Balance - September 30, 2015 6,657 $ 13.09 Exercised (5,714) 17.50 CDN $ Expired (943) 17.50 CDN $ Balance - September 30, 2016 and 2017 - $ - There were no broker units granted during the years ended September 30, 2017, 2016 and 2015. Options The Company has an incentive compensation plan adopted in 2017 (the Plan) administered by the Board of Directors, which amended and restated the 2013 fixed share option plan (the 2013 Plan). Options, restricted shares and restricted share units are eligible for grants under the Plan. The number of shares available for issuance under the Plan is 228,143 The exercise price of an option is set at the closing price of the Company’s common shares on the date of grant. Share options granted to directors, officers, employees and certain individual consultants for past service are subject to the following vesting schedule: (a) one-third shall vest immediately, (b) one-third shall vest at 12 months from the date of grant and (c) one-third shall vest at 18 months from the date of grant. Share options granted to directors, officers, employees and certain individual consultants for future service are subject to the following vesting schedule: (x) one-third shall vest at 12 months from the date of grant, (y) one-third shall vest at 24 months from the date of grant and (z) one-third shall vest at 36 months from the date of grant. Share options granted to certain individual investor relations consultants are subject to the following vesting schedule: (aa) 25% shall vest at 3 months from the date of grant, (bb) 25% shall vest at 6 months from the date of grant, (cc) 25% shall vest at 12 months from the date of grant and (dd) 25% shall vest at 15 months from the date of grant. Weighted Number of Average Options Exercise Price Balance - September 30, 2015 79,663 $ 36.19 Granted 8,043 45.29 Expired (3,048) 74.90 Expired (7,643) 36.54 CDN $ Balance - September 30, 2016 77,015 $ 37.03 Granted 10,229 13.23 Expired (4,033) 77.98 Expired (24,500) 20.30 CDN $ Balance - September 30, 2017 58,711 $ 40.18 The weighted average contractual life remaining on the outstanding options is 35 Number of Exercisable at Options September 30, 2017 Range of exercise prices Expiry Dates 16,444 16,444 CDN$15.00 - 35.00 Apr 2017-Dec 2019 11,415 2,533 $5.00 - 20.00 Sep 2023-Mar 2024 19,980 19,980 CDN$40.00 - 70.00 Oct 2017-Jun 2022 2,157 2,157 $50.00 - 60.00 Dec 2022 3,072 3,072 CDN$105.00 - 140.00 Nov 2018-Nov 2021 5,643 5,643 $120.00 - 130.00 Nov 2020 58,711 49,829 Years Ended September 30, September 30, September 30, 2017 2016 2015 Risk free interest rate 1.44 % 1.01 % 1.65 % Expected life (years) 7.00 7.00 7.00 Expected share price volatility 166 % 117 % 115 % Expected dividend yield 0 % 0 % 0 % The weighted average fair value of share options granted during the years ended September 30, 2017, 2016 and 2015 was $ 12.88 38.92 66.36 As of September 30, 2017, the Company had approximately $ 62,000 30 The intrinsic value of the options exercised during the year ended September 30, 2015 was $ 57.99

Income Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2017
Income Taxes [Abstract]
Income Tax Disclosure [Text Block]	9. Income Taxes The breakdown of loss before income tax by jurisdiction is as follows: Years Ended September 30, September 30, September 30, 2017 2016 2015 U.S. $ (4,540,094 ) $ (4,001,206 ) $ (3,258,355 ) Canadian (464,990 ) (1,026,520 ) 405,203 Other foreign (24,764 ) 8,846 46,923 Total Loss Before Income Tax $ (5,029,848 ) $ (5,018,880 ) $ (2,806,229 ) Deferred income tax assets and liabilities of the Company are as follows: September 30, September 30, September 30, Deferred income tax assets: Non-capital loss carry-forwards $ 12,164,100 $ 10,000,000 $ 8,028,900 Research and development tax credits 947,300 808,000 716,400 Deferred expenses 34,300 70,000 82,900 Property, plant and equipment 2,200 400 1,700 Share issuance costs 142,600 207,200 67,800 Deferred income tax liabilities: U.S. federal benefit net of state taxes (923,700 ) (764,500 ) (628,800 ) Valuation allowance (12,366,800 ) (10,321,100 ) (8,268,900 ) Net deferred income tax asset (liability) $ - $ - $ - Realization of the deferred tax assets is dependent upon the generation of future taxable income, the amount and timing of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. As of September 30, 2017, the Company had federal net operating loss (NOL) carryforwards of approximately $25.3 million expiring 2030 through 2037, California NOL carryforwards of approximately $25.0 million expiring 2018 through 2037, and Canadian federal and provincial NOL carryforwards of approximately CDN$6.8 million expiring 2028 through 2037. Portions of these NOL carryforwards may be used to offset future taxable income, if any. As of September 30, 2017, the Company also has federal and California research and development tax credit carryforwards of approximately $0.45 million and $0.50 million, respectively, available to offset future taxes. The federal credits begin expiring in 2030 and continue expiring through 2037. The state tax credits do not expire. Under the provisions of Section 382 of the Internal Revenue Code, substantial changes in the Company's ownership limit the amount of net operating loss carryforwards and tax credit carryforwards that can be utilized annually in the future to offset taxable income. A valuation allowance has been established to reserve the potential benefits of these carryforwards in the Company's consolidated financial statements to reflect the uncertainty of future taxable income required to utilize available tax loss carryforwards and other deferred tax assets. The recovery of income taxes shown in the consolidated statements of operations differs from the amounts obtained by applying statutory rates to the loss before provision for income taxes due to the following: September 30, September 30, September 30, Combined Canadian federal and provincial tax rates 26.0 % 26.0 % 26.0 % Expected income tax (recovery)/expense $ (1,307,800 ) $ (1,304,900 ) $ (729,600 ) Nondeductible share-based payments 30,000 (67,400 ) 69,500 Nondeductible change in fair value of warrant liability - (55,100 ) (554,100 ) Effect of higher income tax rate in U.S. (624,400 ) (550,600 ) (445,800 ) Foreign currency differences (42,200 ) 20,000 169,900 Other (174,500 ) (2,800 ) (43,300 ) Change in valuation allowance on deferred tax assets 2,119,700 1,968,000 1,570,200 Income tax expense $ 800 $ 7,200 $ 36,800 The components of income tax provision (benefits) are as follows: September 30, September 30, September 30, Current tax provision U.S. federal $ - $ - $ - Canadian - - - Other foreign - 6,400 36,000 State 800 800 800 Deferred tax provision U.S. federal (1,447,100 ) (1,265,700 ) (1,032,200 ) Canadian (199,100 ) (303,300 ) (209,300 ) Other foreign (5,200 ) - - State (468,300 ) (399,000 ) (328,700 ) Change in valuation allowance on deferred tax assets 2,119,700 1,968,000 1,570,200 Total $ 800 $ 7,200 $ 36,800

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended	12 Months Ended
	Mar. 31, 2018	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	8. Fair Value of Financial Instruments The Company uses the fair value measurement framework for valuing financial assets and liabilities measured on a recurring basis in situations where other accounting pronouncements either permit or require fair value measurements. Fair value of a financial instrument is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The carrying value of certain financial instruments such as accounts receivable, accounts payable, accrued liabilities, and deferred revenue approximates fair value due to the short-term nature of such instruments. Short-term investments in U.S. Treasury Bills are recorded at amortized cost, which approximates fair value. The Company follows the fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value: Level 1: Quoted prices in active markets for identical or similar assets and liabilities. Level 2: Quoted prices for identical or similar assets and liabilities in markets that are not active or observable inputs other than quoted prices in active markets for identical or similar assets and liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company reports its short-term investments in U.S. Treasury Bills at fair value using Level 1 inputs in the fair value hierarchy. Fair Value Measurements Using Quoted Prices in Significant Active Markets Other Significant for Identical Observable Unobservable Instruments Inputs Inputs (Level 1) (Level 2) (Level 3) Total Fair Value March 31, 2018 Assets Short-term investments in U.S. Treasury Bills $ 499,623 $ - $ - $ 499,623 September 30, 2017 Assets Short-term investments in U.S. Treasury Bills $ 1,994,401 $ - $ - $ 1,994,401	10. Fair Value of Financial Instruments The Company uses the fair value measurement framework for valuing financial assets and liabilities measured on a recurring basis in situations where other accounting pronouncements either permit or require fair value measurements. Fair value of a financial instrument is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The carrying value of certain financial instruments such as accounts receivable, accounts payable, accrued liabilities, and deferred revenue approximates fair value due to the short-term nature of such instruments. Short-term investments in U.S. Treasury Bills are recorded at amortized cost, which approximates fair value. The Company follows the fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value: Level 1: Quoted prices in active markets for identical or similar assets and liabilities. Level 2: Quoted prices for identical or similar assets and liabilities in markets that are not active or observable inputs other than quoted prices in active markets for identical or similar assets and liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company reports its short-term investments in U.S. Treasury Bills at fair value using Level 1 inputs in the fair value hierarchy. Fair Value Measurements Using Quoted Prices in Significant Active Markets Other Significant for Identical Observable Unobservable Instruments Inputs Inputs (Level 1) (Level 2) (Level 3) Total Fair Value September 30, 2017 Assets Short-term investments in U.S. Treasury Bills $ 1,994,401 $ - $ - $ 1,994,401 September 30, 2016 Assets Short-term investments in U.S. Treasury Bills $ 3,988,794 $ - $ - $ 3,988,794

Concentrations of Credit Risk

Concentrations of Credit Risk	6 Months Ended	12 Months Ended
	Mar. 31, 2018	Sep. 30, 2017
Concentrations of Credit Risk [Abstract]
Concentration Risk Disclosure [Text Block]	9. Concentrations of Credit Risk Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations. Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, U.S Treasury Bills, and accounts receivable. The Company estimates its maximum credit risk at the amount recorded on the balance sheet. Management’s assessment of the Company’s credit risk for cash and cash equivalents is low as they are held in major financial institutions believed to be credit worthy or U.S. Treasury Bills with maturities of 90 days or less. The Company limits its exposure to credit loss for short-term investments by holding U.S. Treasury Bills with maturities of 1 year or less. Based on credit monitoring and history, the Company considers the risk of credit losses due to customer non-performance on accounts receivable to be low. The Company had the following concentrations of revenues by customers, each of which accounted for more than 10% of revenues in the applicable period: Six Months Ended March 31, March 31, 2018 2017 Product sales and contract services revenue 72% from 88% from The Company had the following concentrations of revenues by geographic areas: Six Months Ended March 31, March 31, 2018 2017 North America 81 % 29 % Europe 19 % 71 % The Company had the following concentrations of accounts receivable from its customers, each of which accounted for more than 10% in the applicable period: March 31, 2018 Accounts receivable 67% from There were no customer accounts receivable at September 30, 2017.	11. Concentrations of Credit Risk Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations. Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, U.S Treasury Bills, and accounts receivable. The Company estimates its maximum credit risk at the amount recorded on the balance sheet. Management’s assessment of the Company’s credit risk for cash and cash equivalents is low as they are held in major financial institutions believed to be credit worthy or U.S. Treasury Bills with maturities of 90 days or less. The Company limits its exposure to credit loss for short-term investments by holding U.S. Treasury Bills with maturities of 1 year or less. Based on credit monitoring and history, the Company considers the risk of credit losses due to customer non-performance on accounts receivable to be low. Years Ended September 30, September 30, September 30, 2017 2016 2015 Product sales and contract services revenue 79% from 76% from 86% from The Company had the following concentrations of revenues by geographic areas: Years Ended September 30, September 30, September 30, 2017 2016 2015 Europe 64 % 43 % 53 % North America 33 % 12 % 9 % Asia 3 % 45 % 38 % The Company had the following concentrations of accounts receivable from its customers, each of which accounted for more than 10% in the applicable period: September 30, 2016 Accounts receivable 100% from There were no customer accounts receivable at September 30, 2017.

Subsequent Event

Subsequent Event	12 Months Ended
	Sep. 30, 2017
Subsequent Event [Abstract]
Subsequent Events [Text Block]	12. Subsequent Event On May 4, 2018, the Company effected a share consolidation (reverse split) of the Company's common shares at a ratio of 1-for-7. As a result of the reverse split, every seven shares of the issued and outstanding common shares, without par value, consolidated into one newly-issued outstanding common share, without par value. Each fractional share remaining after the reverse split that was less than one-half of a share was cancelled and each fractional share that was at least one-half of a share was changed to one whole share. The reverse split reduced the number of common shares outstanding from 10,520,096 1,502,870

Significant Accounting Polici19

Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	a) Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reported periods. These estimates include warrant liabilities, share-based compensation, intangible assets, valuation of accounts receivable, valuation of inventory, and income taxes. Actual outcomes could differ from these estimates. These consolidated financial statements include estimates, which by their nature are uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements, and may require accounting adjustments based on future periods if the revision affects both current and future periods. These estimates are based on historical experience, current and future economic conditions and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
Cash and Cash Equivalents, Policy [Policy Text Block]	b) Cash and Cash Equivalents Cash and cash equivalents consist of demand deposits with financial institutions and highly liquid investments which are readily convertible into cash with maturities of three months or less when purchased.
Investment, Policy [Policy Text Block]	c) Investments Investments at September 30, 2017 and 2016 consisted of U.S. Treasury bills with original maturities between 13 and 52 weeks. They are classified as held-to-maturity and are reported at amortized cost, which approximates fair value. The Company regularly reviews these investments to determine whether any decline in fair value below the amortized cost basis has occurred that is other than temporary. If a decline in fair value has occurred that is determined to be other than temporary, the cost basis of the investment is written down to fair value.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	d) Allowance for Doubtful Accounts Receivable The Company assesses the collectability of its accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions and credit status of its customers. As of September 30, 2017 and 2016, all outstanding accounts receivable were deemed to be fully collectible, and therefore, no allowance for doubtful accounts was recorded.
Inventory, Policy [Policy Text Block]	e) Inventory The Company records inventory at the lower of cost or market, with market not in excess of net realizable value. Raw materials are measured using FIFO (first-in first-out) cost. Work in process and finished goods are measured using average cost.
Property, Plant and Equipment, Policy [Policy Text Block]	f) Property, Plant and Equipment Property, plant and equipment are recorded at cost less accumulated depreciation and accumulated impairment losses, if any. Depreciation is recorded on the straight-line method over useful lives ranging from 1.5 15
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	g) Impairment of Long-Lived Assets If indicators of impairment exist, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, the amount of such impairment is measured by comparing the carrying value of the asset to the fair value of the asset and the Company records the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results.
Fair Value of Financial Instruments, Policy [Policy Text Block]	h) Fair Value of Financial Instruments The Company uses the fair value measurement framework for valuing financial assets and liabilities measured on a recurring basis in situations where other accounting pronouncements either permit or require fair value measurements. See Note 10 for fair value measurements.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Product Sales The Company recognizes product sales when KLH product is shipped (for which the risk is typically transferred upon delivery to the shipping carrier) and there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collectability is reasonably assured. The Company documents arrangements with customers with purchase orders and sales agreements. Product sales include sales made under supply agreements with customers for a fixed price per gram of KLH products based on quantities ordered. Supply agreements are typically on a non-exclusive basis except within that customer’s field of use. Contract services revenue The Company recognizes contract services revenue when contract services have been performed and reasonable assurance exists regarding measurement and collectability. An appropriate amount will be recognized as revenue in the period that the Company is assured of fulfilling the contract requirements. Amounts received in advance of performance of contract services are recorded as deferred revenue. Contract services include services performed under collaboration agreements and technology transfer and purchase agreement.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development expenses principally consist of personnel costs related to the Company’s research and development staff as well as depreciation of research and development assets. Research and development expenses also include costs incurred for laboratory supplies , KLH designated for internal research use only Research and development costs are expensed as incurred.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share-Based Compensation The Company grants options to buy common shares of the Company to its directors, officers, employees and consultants, and grants other equity-based instruments to non-employees. The fair value of share-based compensation is measured on the date of grant, using the Black-Scholes option valuation model and is recognized over the vesting period net of estimated forfeitures for employees or the service period for non-employees. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	l) Foreign Exchange Items included in the financial statements of the Company’s subsidiaries are measured using the currency of the primary economic environment in which the entity operates (the functional currency). The functional currency of the parent and its subsidiaries is the U.S. dollar. Transactions in currencies other than the U.S. dollar are recorded at exchange rates prevailing on the dates of the transactions.
Income Tax, Policy [Policy Text Block]	m) Income Taxes Income tax expense comprises current and deferred tax. Income tax is recognized in income or loss except to the extent that it relates to items recognized directly in equity. Current tax expense is the expected tax payable on taxable income for the year, using tax rates enacted or substantively enacted at year-end, adjusted for amendments to tax payable with regards to previous years. Deferred tax is recorded using the liability method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Temporary differences are not provided for relating to goodwill not deductible for tax purposes. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the balance sheet date. A deferred tax asset is recognized only to the extent that it is more likely than not that future taxable profits will be available against which the asset can be utilized. To the extent that the Company does not consider it more likely than not that a deferred tax asset will be recovered, it provides a valuation allowance against that excess. The Company periodically evaluates its tax positions to determine whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities. The Company has not incurred any interest or penalties as of September 30, 2017 with respect to uncertain income tax matters. The Company does not expect that there will be unrecognized tax benefits of a significant nature that will increase or decrease within 12 months of the reporting date. The Company files income tax returns in the U.S. federal and state jurisdictions and in Canada. Mexico tax returns are on a calendar year basis. Management believes that there are no material uncertain tax positions that would impact the accompanying consolidated financial statements. The Company's policy is to recognize interest and penalties related to unrecognized tax benefits in income tax expense. The Company may be subject to examination by the Internal Revenue Service for tax years 2013 through 2016 and by the Canada Revenue Agency for tax years 2013 through 2017. The Company may also be subject to examination on certain state, local and other foreign jurisdictions for the tax years 2012 through 2017.
Earnings Per Share, Policy [Policy Text Block]	n) Earnings (Loss) Per Share Basic earnings (loss) per share is calculated by dividing income available to common shareholders by the weighted average number of common shares outstanding during the period. The computation of diluted earnings (loss) per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on earnings (loss) per share. The dilutive effect of convertible securities is reflected in diluted earnings per share by application of the “if converted” method. The dilutive effect of outstanding options and warrants and their equivalents is reflected in diluted earnings per share by application of the treasury stock method. Conversion of outstanding warrants, broker units and options would have an antidilutive effect on loss per share for the years ended September 30, 2017, 2016 and 2015 and are therefore excluded from the computation of diluted loss per share.
Segment Reporting, Policy [Policy Text Block]	o) Segments The Company operates in one reportable segment and, accordingly, no segment disclosures have been presented. All equipment, leasehold improvements and other fixed assets owned by the Company are physically located within the United States (except for insignificant leasehold improvements under evaluation in Baja California, Mexico), and all supply, collaboration and licensing agreements are denominated in U.S. dollars.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued guidance codified in Accounting Standards Codification (ASC) 606 Revenue Recognition – Revenue from Contracts with Customers which amends the guidance in ASC 605, Revenue Recognition and adds a new Subtopic to the Codification, ASC 340-40, Other Assets and Deferred Costs: Contracts with Customers. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer; Step 2: Identify the performance obligations in the contract; Step 3: Determine the transaction price; Step 4: Allocate the transaction price to the performance obligations in the contract; and Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). In August 2015, the FASB issued an accounting update to defer the effective date by one year for public entities such that it is now effective for public entities for annual reporting periods beginning after December 15, 2017, including interim periods within those years, with early application permitted by one year. Subsequently, the FASB issued supplemental adoption guidance and clarification to ASC 606 related to principal vs. agent considerations, identifying performance obligations and licensing, technical corrections and improvements, which must be adopted at the same time as ASC 606. These standards are effective for the Company during the fiscal year ending September 30, 2019. Management is in the process of assessing the impact this guidance will have on the Company’s consolidated financial statements. We anticipate adoption of ASC 606 using the modified retrospective method with a cumulative catch-up adjustment to the opening balance sheet of retained earnings at the effective date, during the first quarter of fiscal 2019. The Company will continue to review separate performance obligations, potential disclosures, and the method of adoption in order to complete the evaluation of the impact on the consolidated financial statements. In July 2015, FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory within those years In January 2016, the FASB issued ASU 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities primarily affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, ASU 2016-01 The guidance is effective for public entities for fiscal years beginning after December 15, 2017, including interim periods within those years, with early adoption permitted. These standards are effective for the Company during the fiscal year ending September 30, 2019. . In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) Management is in the process of assessing the impact of ASU 2016-02 on the Company’s consolidated financial statements. We anticipate adoption of ASU 2016-02, will result in lease liabilities and right-of-use assets financial statements for several long-term operating leases. In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows . The amended guidance is effective for public entities for fiscal years beginning after December 15, 2016, including interim periods within those years, with early adoption permitted. ASU 2016-09 on financial statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Management is in the process of assessing the impact of ASU 2016-13 on the Company’s consolidated financial statements . In May 2017, the FASB issued ASU 2017-09, Scope of Modification Accounting Compensation-Stock Compensation

Investments (Tables)

Investments (Tables)	12 Months Ended
	Sep. 30, 2017
Investments [Abstract]
Schedule Of Short Term Investments [Table Text Block]	Short-term investments consisted of the following: September 30, September 30, 2017 2016 U.S. Treasury Bills $ 1,994,401 $ 3,988,794

Inventory (Tables)

Inventory (Tables)	6 Months Ended	12 Months Ended
	Mar. 31, 2018	Sep. 30, 2017
Inventory [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory consisted of the following: March 31, September 30, 2018 2017 Raw materials $ 35,514 $ 21,761 Work in process 69,100 - Finished goods 100,750 46,353 $ 205,364 $ 68,114	Inventory consisted of the following: September 30, September 30, 2017 2016 Raw materials $ 21,761 $ 38,764 Work in process - 43,498 Finished goods 46,353 167,168 $ 68,114 $ 249,430

Property, Plant and Equipment22

Property, Plant and Equipment, net (Tables)	6 Months Ended	12 Months Ended
	Mar. 31, 2018	Sep. 30, 2017
Property, Plant and Equipment, net [Abstract]
Property, Plant and Equipment [Table Text Block]	Property, plant and equipment, net consisted of the following: March 31, September 30, 2018 2017 Aquaculture system $ 126,257 $ 126,257 Laboratory facilities 62,033 62,033 Computer and office equipment 119,199 117,840 Manufacturing and laboratory equipment 1,039,643 982,439 Vehicles 77,994 77,994 Leasehold improvements 342,935 337,060 1,768,061 1,703,623 Less: accumulated depreciation (1,054,907) (969,418) Depreciable assets, net 713,154 734,205 Construction in progress 263,782 145,318 $ 976,936 $ 879,523	Property, plant and equipment, net consisted of the following: September 30, September 30, 2017 2016 Aquaculture system $ 126,257 $ 126,257 Laboratory facilities 62,033 62,033 Computer and office equipment 117,840 102,030 Tools and equipment 982,439 894,319 Vehicles 77,994 49,347 Leasehold improvements 337,060 282,305 1,703,623 1,516,291 Less: accumulated depreciation (969,418) (793,057) Depreciable assets, net 734,205 723,234 Construction in progress 145,318 32,880 $ 879,523 $ 756,114

Commitments (Tables)

Commitments (Tables)	6 Months Ended	12 Months Ended
	Mar. 31, 2018	Sep. 30, 2017
Commitments [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Aggregate future minimum lease payments at March 31, 2018 are as follows: Six Months Ending September 30, 2018 71,000 Year Ending September 30, 2019 106,000 Year Ending September 30, 2020 106,000 Year Ending September 30, 2021 6,000 $ 289,000	Aggregate future minimum lease payments at September 30, 2017 are as follows: For The Year Ending September 30, 2018 160,000 2019 106,000 2020 106,000 2021 6,000 $ 378,000

Share Capital (Tables)

Share Capital (Tables)	6 Months Ended	12 Months Ended
	Mar. 31, 2018	Sep. 30, 2017
Class of Warrant or Right [Line Items]
Schedule of Stockholders Equity [Table Text Block]		The Company had the following transactions in share capital: Years Ended September 30, September 30, September 30, 2017 2016 2015 Number of common shares issued 54,834 307,357 6,110 Issuance of common shares $ - $ 6,750,000 $ - Share issuance costs - (805,264) - Proceeds from exercise of warrants - 1,368,260 12,609 Transfer to common shares on issuance of performance shares 1,070,909 - - Transfer to common shares on exercise of warrants - 1,853,581 10,000 Proceeds from exercise of options - - 94,168 Transfer to common shares on exercise of options - - 113,561 Share-based compensation 115,546 259,379 267,222
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]		A summary of the Company’s warrants activity is as follows: Weighted Number of Average Warrants Exercise Price Balance - September 30, 2015 146,110 $ 63.28 Granted 180,805 31.50 Granted 5,715 28.00 CDN $ Exercised (60,572) 28.00 CDN $ Expired (85,538) 93.31 Expired (5,715) 28.00 CDN $ Balance - September 30, 2016 and 2017 180,805 $ 31.50
Schedule Of Warrants Outstanding [Table Text Block]		The following table summarizes information about the warrants outstanding at September 30, 2017: Number of Exercise Price Warrants Expiry Date $ 31.50 180,805 January 6, 2022 180,805
Schedule of Broker Units, Activity [Table Text Block]		A summary of broker units activity is as follows: Weighted Number of Average Units Exercise Price Balance - September 30, 2015 6,657 $ 13.09 Exercised (5,714) 17.50 CDN $ Expired (943) 17.50 CDN $ Balance - September 30, 2016 and 2017 - $ -
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Options have been granted under the Incentive Plan allowing the holders to purchase common shares of the Company as follows: Weighted Number of Average Options Exercise Price Balance - September 30, 2016 77,015 $ 37.03 Granted 10,229 13.23 Expired (4,033) 77.98 Expired (24,500) 20.30 CDN $ Balance - September 30, 2017 58,711 $ 40.18 Granted 29,426 5.88 Expired (1,671) 112.56 Expired (5,679) 36.19 CDN $ Balance - March 31, 2018 80,787 $ 26.46	Options have been granted under the Plan allowing the holders to purchase common shares of the Company as follows: Weighted Number of Average Options Exercise Price Balance - September 30, 2015 79,663 $ 36.19 Granted 8,043 45.29 Expired (3,048) 74.90 Expired (7,643) 36.54 CDN $ Balance - September 30, 2016 77,015 $ 37.03 Granted 10,229 13.23 Expired (4,033) 77.98 Expired (24,500) 20.30 CDN $ Balance - September 30, 2017 58,711 $ 40.18
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	The following table summarizes information about the options under the Incentive Plan outstanding and exercisable at March 31, 2018: Number of Exercisable at Options March 31, 2018 Range of exercise prices Expiry Dates 13,479 13,479 CDN$15.00 - 35.00 Apr 2019-Dec 2019 40,641 15,859 $5.00 - 20.00 Sep 2023-Mar 2025 17,265 17,265 CDN$40.00 - 70.00 Aug 2018-Jun 2022 2,114 2,114 $50.00 - 60.00 Dec 2022 3,073 3,073 CDN$105.00 - 140.00 Nov 2018-Nov 2021 4,215 4,215 $120.00 - 130.00 Nov 2020 80,787 56,005	The following table summarizes information about the options under the Plan outstanding and exercisable at September 30, 2017: Number of Exercisable at Options September 30, 2017 Range of exercise prices Expiry Dates 16,444 16,444 CDN$15.00 - 35.00 Apr 2017-Dec 2019 11,415 2,533 $5.00 - 20.00 Sep 2023-Mar 2024 19,980 19,980 CDN$40.00 - 70.00 Oct 2017-Jun 2022 2,157 2,157 $50.00 - 60.00 Dec 2022 3,072 3,072 CDN$105.00 - 140.00 Nov 2018-Nov 2021 5,643 5,643 $120.00 - 130.00 Nov 2020 58,711 49,829
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The estimated fair value of the share options granted during the six months ended March 31, 2018 and 2017 was determined using a Black-Scholes option valuation model with the following weighted average assumptions: Six Months Ended March 31, March 31, 2018 2017 Risk free interest rate 2.13 % 1.44 % Expected life (years) 7.00 7.00 Expected share price volatility 155 % 166 % Expected dividend yield 0 % 0 %	The estimated fair value of the share options granted was determined using a Black-Scholes option valuation model with the following weighted average assumptions: Years Ended September 30, September 30, September 30, 2017 2016 2015 Risk free interest rate 1.44 % 1.01 % 1.65 % Expected life (years) 7.00 7.00 7.00 Expected share price volatility 166 % 117 % 115 % Expected dividend yield 0 % 0 % 0 %
Warrants Exercised [Member]
Class of Warrant or Right [Line Items]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]		The fair value of warrants exercised was determined using the Black-Scholes option valuation model, using the following weighted average assumptions: Years Ended September 30, September 30, 2016 2015 Risk free interest rate 0.48 % 0.44 % Expected life (years) 0.04 0.40 Expected share price volatility 92 % 92 %
Warrants Granted [Member]
Class of Warrant or Right [Line Items]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]		The fair value of warrants granted was determined using the Black-Scholes option valuation model, using the following weighted average assumptions at the date of the grant: Year Ended September 30, 2016 Risk free interest rate 0.52 % Expected life (years) 0.01 Expected share price volatility 91 % Expected dividend yield 0 %

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2017
Income Taxes [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	The breakdown of loss before income tax by jurisdiction is as follows: Years Ended September 30, September 30, September 30, 2017 2016 2015 U.S. $ (4,540,094) $ (4,001,206) $ (3,258,355) Canadian (464,990) (1,026,520) 405,203 Other foreign (24,764) 8,846 46,923 Total Loss Before Income Tax $ (5,029,848) $ (5,018,880) $ (2,806,229)
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Deferred income tax assets and liabilities of the Company are as follows: September 30, September 30, September 30, 2017 2016 2015 Deferred income tax assets: Non-capital loss carry-forwards $ 12,164,100 $ 10,000,000 $ 8,028,900 Research and development tax credits 947,300 808,000 716,400 Deferred expenses 34,300 70,000 82,900 Property, plant and equipment 2,200 400 1,700 Share issuance costs 142,600 207,200 67,800 Deferred income tax liabilities: U.S. federal benefit net of state taxes (923,700) (764,500) (628,800) Valuation allowance (12,366,800) (10,321,100) (8,268,900) Net deferred income tax asset (liability) $ - $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The recovery of income taxes shown in the consolidated statements of operations differs from the amounts obtained by applying statutory rates to the loss before provision for income taxes due to the following: September 30, September 30, September 30, 2017 2016 2015 Combined Canadian federal and provincial tax rates 26.0 % 26.0 % 26.0 % Expected income tax (recovery)/expense $ (1,307,800) $ (1,304,900) $ (729,600) Nondeductible share-based payments 30,000 (67,400) 69,500 Nondeductible change in fair value of warrant liability - (55,100) (554,100) Effect of higher income tax rate in U.S. (624,400) (550,600) (445,800) Foreign currency differences (42,200) 20,000 169,900 Other (174,500) (2,800) (43,300) Change in valuation allowance on deferred tax assets 2,119,700 1,968,000 1,570,200 Income tax expense $ 800 $ 7,200 $ 36,800
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The components of income tax provision (benefits) are as follows: September 30, September 30, September 30, 2017 2016 2015 Current tax provision U.S. federal $ - $ - $ - Canadian - - - Other foreign - 6,400 36,000 State 800 800 800 Deferred tax provision U.S. federal (1,447,100) (1,265,700) (1,032,200) Canadian (199,100) (303,300) (209,300) Other foreign (5,200) - - State (468,300) (399,000) (328,700) Change in valuation allowance on deferred tax assets 2,119,700 1,968,000 1,570,200 Total $ 800 $ 7,200 $ 36,800

Fair Value of Financial Instr26

Fair Value of Financial Instruments (Tables)	6 Months Ended	12 Months Ended
	Mar. 31, 2018	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The following table summarizes fair values for those assets and liabilities with fair value measured on a recurring basis. Fair Value Measurements Using Quoted Prices in Significant Active Markets Other Significant for Identical Observable Unobservable Instruments Inputs Inputs (Level 1) (Level 2) (Level 3) Total Fair Value March 31, 2018 Assets Short-term investments in U.S. Treasury Bills $ 499,623 $ - $ - $ 499,623 September 30, 2017 Assets Short-term investments in U.S. Treasury Bills $ 1,994,401 $ - $ - $ 1,994,401	The following table summarizes fair values for those assets and liabilities with fair value measured on a recurring basis. Fair Value Measurements Using Quoted Prices in Significant Active Markets Other Significant for Identical Observable Unobservable Instruments Inputs Inputs (Level 1) (Level 2) (Level 3) Total Fair Value September 30, 2017 Assets Short-term investments in U.S. Treasury Bills $ 1,994,401 $ - $ - $ 1,994,401 September 30, 2016 Assets Short-term investments in U.S. Treasury Bills $ 3,988,794 $ - $ - $ 3,988,794

Concentrations of Credit Risk (

Concentrations of Credit Risk (Tables)	6 Months Ended	12 Months Ended
	Mar. 31, 2018	Sep. 30, 2017
Concentrations of Credit Risk [Abstract]
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	The Company had the following concentrations of revenues by customers, each of which accounted for more than 10% of revenues in the applicable period: Six Months Ended March 31, March 31, 2018 2017 Product sales and contract services revenue 72% from 88% from The Company had the following concentrations of revenues by geographic areas: Six Months Ended March 31, March 31, 2018 2017 North America 81 % 29 % Europe 19 % 71 % The Company had the following concentrations of accounts receivable from its customers, each of which accounted for more than 10% in the applicable period: March 31, 2018 Accounts receivable 67% from	Years Ended September 30, September 30, September 30, 2017 2016 2015 Product sales and contract services revenue 79% from 76% from 86% from The Company had the following concentrations of revenues by geographic areas: Years Ended September 30, September 30, September 30, 2017 2016 2015 Europe 64 % 43 % 53 % North America 33 % 12 % 9 % Asia 3 % 45 % 38 % The Company had the following concentrations of accounts receivable from its customers, each of which accounted for more than 10% in the applicable period: September 30, 2016 Accounts receivable 100% from

Nature of Operations (Details T

Nature of Operations (Details Textual) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2015
Nature of Operations [Line Items]
Net Income (Loss)	$ (1,352,527)	$ (1,103,677)	$ (2,753,273)	$ (2,589,349)	$ (5,030,648)	$ (5,026,080)	$ (2,843,029)
Accumulated deficit	(48,145,316)		(48,145,316)		(45,392,043)	$ (40,361,395)
Working capital	$ 3,700,000		$ 3,700,000		$ 6,400,000

Significant Accounting Polici29

Significant Accounting Policies (Details Textual)	12 Months Ended
	Sep. 30, 2017
Minimum [Member]
Significant Accounting Policies Disclosure [Line Items]
Property, plant and equipment, useful lives	1 year 6 months
Maximum [Member]
Significant Accounting Policies Disclosure [Line Items]
Property, plant and equipment, useful lives	15 years

Investments (Details)

Investments (Details) - USD ($)	Sep. 30, 2017	Sep. 30, 2016
U.S. Treasury Bills	$ 1,994,401	$ 3,988,794

Inventory (Details)

Inventory (Details) - USD ($)	Mar. 31, 2018	Sep. 30, 2017	Sep. 30, 2016
Raw materials	$ 35,514	$ 21,761	$ 38,764
Work in process	69,100	0	43,498
Finished goods	100,750	46,353	167,168
Inventory	$ 205,364	$ 68,114	$ 249,430

Property, Plant and Equipment32

Property, Plant and Equipment, net (Details) - USD ($)	Mar. 31, 2018	Sep. 30, 2017	Sep. 30, 2016
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	$ 1,768,061	$ 1,703,623	$ 1,516,291
Less: accumulated depreciation	(1,054,907)	(969,418)	(793,057)
Depreciable assets, net	713,154	734,205	723,234
Construction in progress	263,782	145,318	32,880
Property, plant and equipment, net	976,936	879,523	756,114
Aquaculture system [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	126,257	126,257	126,257
Laboratory facilities [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	62,033	62,033	62,033
Computer and office equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	119,199	117,840	102,030
Tools, Manufacturing and laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	1,039,643	982,439	894,319
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	77,994	77,994	49,347
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	$ 342,935	$ 337,060	$ 282,305

Property, Plant and Equipment33

Property, Plant and Equipment, net (Details Textual) - USD ($)	6 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2015
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 96,000	$ 91	$ 179,322	$ 149,565	$ 159,521

Commitments (Details)

Commitments (Details) - USD ($)	Mar. 31, 2018	Sep. 30, 2017
Future minimum lease payments for the
Six Months Ending September 30, 2018	$ 71,000	$ 160,000
Year Ending September 30, 2019	106,000	106,000
Year Ending September 30, 2020	106,000	106,000
Year Ending September 30, 2021	6,000	6,000
Future minimum lease payments, total	$ 289,000	$ 378,000

Commitments (Details Textual)

Commitments (Details Textual)	6 Months Ended		12 Months Ended
	Mar. 31, 2018USD ($)	Mar. 31, 2017USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2016EUR (€)	Aug. 14, 2002USD ($)
Other Commitments [Line Items]
Rent expense on lease agreements	$ 120,000	$ 119,000	$ 238,000	$ 235,000	$ 192,000
Equity Method Investments	66,695		66,695	$ 66,695
Long-term Purchase Commitment, Amount			65,100
Joint venture agreement [Member]
Other Commitments [Line Items]
Equity Method Investments Committed Capital | €						€ 120,000
Equity Method Investment, Ownership Percentage				30.00%		30.00%
Equity Method Investments				$ 67,000
Director and Officer [Member] | Royalty Agreements [Member]
Other Commitments [Line Items]
Royalty percentage of gross receipts over base amount							5.00%
Gross receipt base amount for royalty calculation							$ 500,000
Royalty expense	0	0	0	35,500	1,500
Licensing Agreements [Member]
Other Commitments [Line Items]
Annual license fee				20,000	20,000
Patent cost reimbursement			12,000	11,000	52,000
401(k) Retirement Savings Plan [Member]
Other Commitments [Line Items]
Employer contributions	$ 38,000	$ 32,000	$ 62,000	$ 64,000	$ 58,000
Employee vesting percentage	100.00%		100.00%
Annual non-elective safe harbor employer contribution	3.00%		3.00%
Agreements With Contract Manufacturing Organizations And Consultants [Member]
Other Commitments [Line Items]
Purchase obligations	$ 153,000		$ 252,000
Three buildings and facilities used in its operations [Member]
Other Commitments [Line Items]
Lease agreement, contract term	5 years		5 years
Lease agreement, renewal term	5 years		5 years
Facilities used for executive offices and laboratories [Member]
Other Commitments [Line Items]
Lease agreement, renewal term	2 years		2 years
Undeveloped land in Baja, Mexico
Other Commitments [Line Items]
Lease agreement, renewal term	3 years		3 years
Undeveloped land in Baja, Mexico | Licensing Agreements [Member]
Other Commitments [Line Items]
Lease agreement, renewal term			30 years

Share Capital (Details)

Share Capital (Details) - USD ($)	12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2015
Class of Warrant or Right [Line Items]
Issuance of common shares		$ 6,750,000
Share issuance costs		(805,264)
Proceeds from exercise of warrants		1,368,260	$ 12,609
Transfer to common shares on exercise of warrants		1,762,586	9,574
Proceeds from exercise of options			94,168
Share-based compensation	$ 115,546	$ 259,379	$ 267,222
Share Capital [Member]
Class of Warrant or Right [Line Items]
Number of common shares issued	54,834	307,357	6,110
Issuance of common shares	$ 0	$ 6,750,000	$ 0
Share issuance costs	0	(805,264)	0
Proceeds from exercise of warrants	0	1,368,260	12,609
Transfer to common shares on issuance of performance shares	1,070,909	0	0
Transfer to common shares on exercise of warrants	0	1,853,581	10,000
Proceeds from exercise of options	0	0	94,168
Transfer to common shares on exercise of options	0	0	113,561
Share-based compensation	$ 115,546	$ 259,379	$ 267,222

Share Capital (Details 1)

Share Capital (Details 1)	12 Months Ended
	Sep. 30, 2017$ / sharesshares	Sep. 30, 2016$ / sharesshares	Sep. 30, 2016$ / sharesshares
Class of Warrant or Right [Line Items]
Number of Warrants, Beginning Balance	180,805	146,110	146,110
Number of Warrants, Granted		180,805	180,805
Number of Warrants, Granted		5,715	5,715
Number of Warrants, Exercised		(60,572)	(60,572)
Number of Warrants, Expired		(85,538)	(85,538)
Number of Warrants, Expired		(5,715)	(5,715)
Number of Warrants, Ending Balance	180,805	180,805	180,805
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 31.50	$ 63.28
Weighted Average Exercise Price, Granted | (per share)		31.50	$ 28
Weighted Average Exercise Price, Exercised | $ / shares			28
Weighted Average Exercise Price, Expired | (per share)		93.31	$ 28
Weighted Average Exercise Price, Ending Balance | $ / shares	$ 31.50	$ 31.50

Share Capital (Details 2)

Share Capital (Details 2) - $ / shares	12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2015
Class of Warrant or Right [Line Items]
Exercise Price	$ 31.50	$ 31.50	$ 63.28
Number of Warrants	180,805	180,805	146,110
Expiry Date	Jan. 6, 2022

Share Capital (Details 3)

Share Capital (Details 3) - Warrants Exercised [Member]	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Class of Warrant or Right [Line Items]
Risk free interest rate	0.48%	0.44%
Expected life (years)	14 days	4 months 24 days
Expected share price volatility	92.00%	92.00%

Share Capital (Details 4)

Share Capital (Details 4) - Warrants Granted [Member]	12 Months Ended
	Sep. 30, 2016
Class of Warrant or Right [Line Items]
Risk free interest rate	0.52%
Expected life (years)	4 days
Expected share price volatility	91.00%
Expected dividend yield	0.00%

Share Capital (Details 5)

Share Capital (Details 5)	12 Months Ended
	Sep. 30, 2017$ / sharesshares	Sep. 30, 2017$ / sharesshares
Class of Stock [Line Items]
Number of units, Beginning Balance | shares	6,657	6,657
Number of units, Exercised | shares	(5,714)	(5,714)
Number of units, Expired | shares	(943)	(943)
Number of units, Ending Balance | shares	0	0
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 17.50
Weighted Average Exercise Price, Exercised | $ / shares		$ 17.50
Weighted Average Exercise Price, Expired | $ / shares		$ 17.50
Weighted average exercise price, Ending Balance | $ / shares	$ 0

Share Capital (Details 6)

Share Capital (Details 6)	6 Months Ended		12 Months Ended
	Mar. 31, 2018$ / sharesshares	Mar. 31, 2018$ / sharesshares	Sep. 30, 2017$ / sharesshares	Sep. 30, 2017$ / sharesshares	Sep. 30, 2016$ / sharesshares	Sep. 30, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Beginning Balance	58,711	58,711
Number of Options, Ending Balance	80,787	80,787	58,711	58,711
2013 Fixed Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Beginning Balance	58,711	58,711	77,015	77,015	79,663	79,663
Number of Options, Granted	29,426	29,426	10,229	10,229	8,043	8,043
Number of Options, Expired	(1,671)	(1,671)	(4,033)	(4,033)	(3,048)	(3,048)
Number of Options, Expired	(5,679)	(5,679)	(24,500)	(24,500)	(7,643)	(7,643)
Number of Options, Ending Balance	80,787	80,787	58,711	58,711	77,015	77,015
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 40.18		$ 37.03		$ 36.19
Weighted Average Exercise Price, Granted | $ / shares	5.88		13.23		45.29
Weighted Average Exercise Price, Expired | $ / shares	112.56		77.98		74.90
Weighted Average Exercise Price, Expired | $ / shares		$ 36.19		$ 20.30		$ 36.54
Weighted Average Exercise Price, Ending Balance | $ / shares	$ 26.46		$ 40.18		$ 37.03

Share Capital (Details 7)

Share Capital (Details 7)	6 Months Ended		12 Months Ended
	Mar. 31, 2018$ / sharesshares	Mar. 31, 2018$ / sharesshares	Sep. 30, 2017$ / sharesshares	Sep. 30, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	80,787	80,787	58,711	58,711
Exercisable	56,005	56,005	49,829	49,829
Stock Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	13,479	13,479	16,444	16,444
Exercisable	13,479	13,479	16,444	16,444
Exercise Price Range, Lower Range Limit | $ / shares		$ 15		$ 15
Exercise Price Range, Upper Range Limit | $ / shares		$ 35		$ 35
Expiry Date, Start	2019-04	2019-04	2017-04	2017-04
Expiry Date, End	2019-12	2019-12	2019-12	2019-12
Stock Option Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	40,641	40,641	11,415	11,415
Exercisable	15,859	15,859	2,533	2,533
Exercise Price Range, Lower Range Limit | $ / shares	$ 5		$ 5
Exercise Price Range, Upper Range Limit | $ / shares	$ 20		$ 20
Expiry Date, Start	2023-09	2023-09	2023-09	2023-09
Expiry Date, End	2025-03	2025-03	2024-03	2024-03
Stock Option Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	17,265	17,265	19,980	19,980
Exercisable	17,265	17,265	19,980	19,980
Exercise Price Range, Lower Range Limit | $ / shares		$ 40		$ 40
Exercise Price Range, Upper Range Limit | $ / shares		$ 70		$ 70
Expiry Date, Start	2018-08	2018-08	2017-10	2017-10
Expiry Date, End	2022-06	2022-06	2022-06	2022-06
Stock Option Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	2,114	2,114	2,157	2,157
Exercisable	2,114	2,114	2,157	2,157
Exercise Price Range, Lower Range Limit | $ / shares	$ 50		$ 50
Exercise Price Range, Upper Range Limit | $ / shares	$ 60		$ 60
Expiry Date, End	2022-12	2022-12	2022-12	2022-12
Stock Option Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	3,073	3,073	3,072	3,072
Exercisable	3,073	3,073	3,072	3,072
Exercise Price Range, Lower Range Limit | $ / shares		$ 105		$ 105
Exercise Price Range, Upper Range Limit | $ / shares		$ 140		$ 140
Expiry Date, Start	2018-11	2018-11	2018-11	2018-11
Expiry Date, End	2021-11	2021-11	2021-11	2021-11
Stock Option Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	4,215	4,215	5,643	5,643
Exercisable	4,215	4,215	5,643	5,643
Exercise Price Range, Lower Range Limit | $ / shares	$ 120		$ 120
Exercise Price Range, Upper Range Limit | $ / shares	$ 130		$ 130
Expiry Date, End	2020-11	2020-11	2020-11	2020-11

Share Capital (Details 8)

Share Capital (Details 8)	6 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	2.13%	1.44%
Expected life (years)	7 years	7 years
Expected share price volatility	155.00%	166.00%
Expected dividend yield	0.00%	0.00%
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate			1.44%	1.01%	1.65%
Expected life (years)			7 years	7 years	7 years
Expected share price volatility			166.00%	117.00%	115.00%
Expected dividend yield			0.00%	0.00%	0.00%

Share Capital (Details Textual)

Share Capital (Details Textual) - USD ($)	May 04, 2018	Mar. 31, 2018	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2010
Share Capital [Line Items]
Stock split, description				As a result of the reverse split, every ten shares of the issued and outstanding common shares, without par value, consolidated into one newly-issued outstanding common share, without par value. Each fractional share remaining after the reverse split that was less than one-half of a share was cancelled and each fractional share that was at least one-half of a share was changed to one whole share.
Weighted average contractual life remaining on the outstanding warrants		45 months		51 months
Weighted average contractual life remaining on the outstanding options				35 months
Weighted average fair value of share options awarded		$ 5.67	$ 12.88	$ 12.88	$ 38.92	$ 66.36
Unrecognized share-based compensation expense		$ 137,000		$ 62,000
Unrecognized share-based compensation expense, recognition period		34 months		30 months
Intrinsic value of the options exercised						$ 57.99
Weighted Average Contractual Life Remaining		45 months		51 months
Subsequent Event [Member]
Share Capital [Line Items]
Stockholders' Equity, Reverse Stock Split	the Company's common shares at a ratio of 1-for-7
Performance Shares [Member]
Share Capital [Line Items]
Share based compensation, shares reserved for issuance							142,857
Employee Share Option [Member]
Share Capital [Line Items]
Share based compensation, shares reserved for issuance				228,143
Share based compensation, share option vesting schedule		Share options granted to directors, officers, employees and certain individual consultants for future service are subject to the following vesting schedule: (x) one-third shall vest at 12 months from the date of grant, (y) one-third shall vest at 24 months from the date of grant and (z) one-third shall vest at 36 months from the date of grant.		Share options granted to directors, officers, employees and certain individual consultants for past service are subject to the following vesting schedule: (a) one-third shall vest immediately, (b) one-third shall vest at 12 months from the date of grant and (c) one-third shall vest at 18 months from the date of grant.

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2015
Income Tax Contingency [Line Items]
U.S.					$ (4,540,094)	$ (4,001,206)	$ (3,258,355)
Canadian					(464,990)	(1,026,520)	405,203
Other foreign					(24,764)	8,846	46,923
Loss Before Income Tax	$ (1,352,527)	$ (1,103,677)	$ (2,752,473)	$ (2,588,549)	$ (5,029,848)	$ (5,018,880)	$ (2,806,229)

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2015
Deferred income tax assets:
Non-capital loss carry-forwards	$ 12,164,100	$ 10,000,000	$ 8,028,900
Research and development tax credits	947,300	808,000	716,400
Deferred expenses	34,300	70,000	82,900
Property, plant and equipment	2,200	400	1,700
Share issuance costs	142,600	207,200	67,800
Deferred income tax liabilities:
U.S. federal benefit net of state taxes	(923,700)	(764,500)	(628,800)
Valuation allowance	(12,366,800)	(10,321,100)	(8,268,900)
Net deferred income tax asset (liability)	$ 0	$ 0	$ 0

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2015
Income Tax Contingency [Line Items]
Combined Canadian federal and provincial tax rates					26.00%	26.00%	26.00%
Expected income tax (recovery)/expense					$ (1,307,800)	$ (1,304,900)	$ (729,600)
Nondeductible share-based payments					30,000	(67,400)	69,500
Nondeductible change in fair value of warrant liability					0	(55,100)	(554,100)
Effect of higher income tax rate in U.S.					(624,400)	(550,600)	(445,800)
Foreign currency differences					(42,200)	20,000	169,900
Other					(174,500)	(2,800)	(43,300)
Change in valuation allowance on deferred tax assets					2,119,700	1,968,000	1,570,200
Income tax expense	$ 0	$ 0	$ 800	$ 800	$ 800	$ 7,200	$ 36,800

Income Taxes (Details 3)

Income Taxes (Details 3) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2015
Current tax provision
U.S. federal					$ 0	$ 0	$ 0
Canadian					0	0	0
Other foreign					0	6,400	36,000
State					800	800	800
Deferred tax provision
U.S. federal					(1,447,100)	(1,265,700)	(1,032,200)
Canadian					(199,100)	(303,300)	(209,300)
Other foreign					(5,200)	0	0
State					(468,300)	(399,000)	(328,700)
Change in valuation allowance on deferred tax assets					2,119,700	1,968,000	1,570,200
Income tax expense	$ 0	$ 0	$ 800	$ 800	$ 800	$ 7,200	$ 36,800

Income Taxes (Details Textual)

Income Taxes (Details Textual) - 12 months ended Sep. 30, 2017 $ in Thousands, $ in Millions	USD ($)	CAD ($)
Federal [Member]
Income Tax [Line Items]
Operating Loss Carryforwards	$ 25,300
Federal [Member] | Earliest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2030
Federal [Member] | Latest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2037
Federal [Member] | Research Tax Credit Carryforward [Member]
Income Tax [Line Items]
Tax Credit Carryforward, Amount	$ 450
Federal [Member] | Research Tax Credit Carryforward [Member] | Earliest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2030
Federal [Member] | Research Tax Credit Carryforward [Member] | Latest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2037
California [Member]
Income Tax [Line Items]
Operating Loss Carryforwards	$ 25,000
California [Member] | Earliest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2018
California [Member] | Latest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2037
California [Member] | Research Tax Credit Carryforward [Member]
Income Tax [Line Items]
Tax Credit Carryforward, Amount	$ 500
Canadian [Member]
Income Tax [Line Items]
Operating Loss Carryforwards		$ 6.8
Canadian [Member] | Earliest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2028
Canadian [Member] | Latest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2037

Fair Value of Financial Instr51

Fair Value of Financial Instruments (Details) - USD ($)	Mar. 31, 2018	Sep. 30, 2017	Sep. 30, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments in U.S. Treasury Bills	$ 499,623	$ 1,994,401	$ 3,988,794
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments in U.S. Treasury Bills	499,623	1,994,401	3,988,794
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments in U.S. Treasury Bills	0	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments in U.S. Treasury Bills	$ 0	$ 0	$ 0

Concentrations of Credit Risk52

Concentrations of Credit Risk (Details)	6 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2015
Customer Concentration Risk [Member] | Product sales and contract services revenue [Member] | Five Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage					86.00%
Customer Concentration Risk [Member] | Product sales and contract services revenue [Member] | Three Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage				76.00%
Customer Concentration Risk [Member] | Product sales and contract services revenue [Member] | Two Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage	72.00%	88.00%	79.00%
Customer Concentration Risk [Member] | Accounts receivable [Member] | One Customer [Member]
Concentration Risk [Line Items]
Concentration risk percentage	67.00%			100.00%
Geographic Concentration Risk [Member] | Revenue [Member] | Europe [Member]
Concentration Risk [Line Items]
Concentration risk percentage	19.00%	71.00%	64.00%	43.00%	53.00%
Geographic Concentration Risk [Member] | Revenue [Member] | Asia [Member]
Concentration Risk [Line Items]
Concentration risk percentage			3.00%	45.00%	38.00%
Geographic Concentration Risk [Member] | Revenue [Member] | North America [Member]
Concentration Risk [Line Items]
Concentration risk percentage	81.00%	29.00%	33.00%	12.00%	9.00%

Subsequent Event (Details Textu

Subsequent Event (Details Textual) - shares	May 04, 2018	Mar. 31, 2018	Sep. 30, 2017	Sep. 30, 2016
Subsequent Event [Line Items]
Common Stock, Shares, Outstanding		1,502,870	1,502,870	1,448,036
Subsequent Event [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Outstanding	10,520,096
Stock Issued During Period, Shares, Reverse Stock Splits	1,502,870
Stockholders Equity, Reverse Stock Split	the Company's common shares at a ratio of 1-for-7